Distinguishing chronic myeloid leukemia in megakaryocytic blast crisis from <i>de novo</i> Ph+ acute megakaryoblastic leukemia: a case report and systematic review. [PDF]
Liu Q, Yu P, Li X, Lan H, Liu Z.
europepmc +1 more source
Investigating the Impact of Protein Supplementation from Different Sources on Advanced Glycation End Products in Older Adults in Singapore Following a Healthy Dietary Pattern. [PDF]
Ting M +5 more
europepmc +1 more source
Malignant remodeling of the bone marrow microenvironment in acute myeloid leukemia: mechanisms and therapeutic implications. [PDF]
Xu W, Han Q, Sun C, Li D.
europepmc +1 more source
Antiglycation approach in selected autoimmune diseases: Where do we stand? [PDF]
Drygała S, Cemaga R, Maciejczyk M.
europepmc +1 more source
Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. [PDF]
Shirity ZNA +9 more
europepmc +1 more source
The Transepithelial Transport and Transport Pathways of Free and Bound Nε-Carboxymethyllysine Using a Caco-2 Cell Monolayer Model. [PDF]
Yuan X +6 more
europepmc +1 more source
Related searches:
The discovery of the tyrosine kinase inhibitor (TKI) imatinib in the early 2000's revolutionized the treatment and prognosis of patients with chronic myeloid leukemia (CML) [Hochhaus et al. in N Engl J Med 376:917-927, 2017]. The treatment of patients with CML has changed dramatically since the approval of imatinib and other TKIs.
openaire +2 more sources
Abstract Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium, the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As such, the question of life expectancy and survival has become less problematic while quality of life and family planning have become more so ...
Harry F, Robertson, Jane F, Apperley
openaire +2 more sources

